Progyny’s (PGNY) Buy Rating Reiterated at Truist Financial

Progyny (NASDAQ:PGNY – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Truist Financial in a research note issued on Tuesday, Benzinga reports. They currently have a $42.00 target price on the stock, up from their prior target price of $36.00. Truist Financial‘s price target suggests a potential upside of 14.53% from the stock’s previous close.

A number of other analysts have also recently commented on the company. Cantor Fitzgerald boosted their price objective on Progyny from $31.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Citizens Jmp lifted their price objective on Progyny from $33.00 to $38.00 and gave the stock a “market outperform” rating in a research report on Thursday, November 5th. JPMorgan Chase & Co. upped their target price on Progyny from $30.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, November 9th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Wells Fargo & Company lifted their price target on Progyny from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Progyny has a consensus rating of “Moderate Buy” and a consensus target price of $35.83.

Check Out Our Latest Stock Analysis on Progyny

Progyny Stock Performance

Shares of NASDAQ PGNY opened at $36.67 on Tuesday. The company has a market capitalization of $2.70 billion, a PE ratio of 33.86, a price-to-earnings-growth ratio of 1.70 and a beta of 0.97. The company’s fifty day moving average price is $28.70 and its 200 day moving average price is $24.94. Progyny has a 1 year low of $16.10 and a 1 year high of $37.20.

Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. The company had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.15 earnings per share. On average, equities analysts expect that Progyny will post 1.43 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, insider Geoffrey Clapp sold 774 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $36.41, for a total value of $28,181.34. Following the completion of the transaction, the insider owned 58,235 shares of the company’s stock, valued at approximately $2,120,336.35. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Livingston sold 2,139 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total value of $64,170.00. Following the sale, the chief financial officer directly owned 70,314 shares in the company, valued at $2,109,420. This represents a 2.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 630,072 shares of company stock valued at $22,363,084. Corporate insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Progyny during the 2nd quarter worth $334,426,000. Bank of America Corp DE boosted its stake in shares of Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after acquiring an additional 511,609 shares in the last quarter. William Blair Investment Management LLC grew its stake in Progyny by 10.7% in the 3rd quarter. William Blair Investment Management LLC now owns 645,130 shares of the company’s stock valued at $16,251,000 after acquiring an additional 62,178 shares during the last quarter. Principal Financial Group Inc. increased its position in Progyny by 16.4% during the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after purchasing an additional 78,198 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Progyny by 23.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 530,279 shares of the company’s stock valued at $13,358,000 after acquiring an additional 100,335 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

(Get Free Report)

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Further Reading

Analyst Recommendations for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.